PR97476

SHANGHAI, Aug. 18, 2022 /PRNewswire=KYODO JBN/ --

Jemincare, a leading pharmaceutical company from China, announced today that it

and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co.,

Ltd., have entered into an exclusive worldwide license agreement with Roche

(SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for

the development and commercialization of its androgen receptor degrader,

JMKX002992.

Under the terms of the agreement, Genentech will be granted an exclusive

license to develop and commercialize the degrader worldwide, and will be fully

responsible for the development and commercialization costs. In return,

Genentech will pay Jemincare a USD 60 million upfront payment. Jemincare is

also entitled to receive up to USD 590 million in additional payments upon

achievement of certain development, regulatory and sales-based milestone

targets. Jemincare is also entitled to receive tiered royalties on net sales.

JMKX002992 is a novel oral degrader of the androgen receptor, a confirmed

disease driver in prostate cancer. JMKX002992 has the potential to treat

patients with prostate cancer who have developed resistance to current

therapies.

"We are delighted to enter into collaboration with Roche, one of the world's

leading pharmaceutical companies providing transformative innovative solutions

across major disease areas, and Genentech, a worldwide leading innovator in

oncology. We trust this partnership could significantly enhance and accelerate

the development and potential commercialization of JMKX002992 to benefit

patients. This is our third innovative therapy partnered globally. We are proud

of this achievement within only four years since the establishment of our R&D

center. Jemincare will continue to realize our commitment to benefit patients

with innovative solutions." said Mr. Hong Liang, President of Jemincare

Pharmaceutical Group.

"Prostate cancer remains a leading cause of death in men worldwide," said James

Sabry, Global Head of Roche Pharma Partnering. "Certain forms of prostate

cancer can be particularly difficult to treat. Jemincare's novel oral androgen

receptor degrader will complement our efforts to develop new treatment options

for patients with advanced prostate cancer."

About Jemincare

Jiangxi Jemincare Group Co., Ltd. is a leading pharmaceutical company from

China. Founded in 1999, Jemincare is mainly engaged in pharmaceutical industry.

The company is dedicated to the development, manufacturing and

commercialization of therapeutics in its strategic fields including oncology,

nephrology, cerebro-cardiovascular, anti-infection, analgesic, respiratory and

Pediatrics. Shanghai Jemincare Pharmaceutical Co., Ltd is the R&D center of

Jiangxi Jemincare Group Co., Ltd. Shanghai Jemincare has developed a strong

team with around 500 scientists comprised by 3 innovation centers, Small

Molecule Innovative Center, Biologics Innovation Center and Technology

Innovation Center. The androgen receptor degrader program was developed by the

Small Molecule Innovation Center which had more than 10 programs entering IND

or IND-enabling stage and 3 programs entering clinical stage. For more

information, please visit www.jemincare.com

Source: Jemincare